61.10 0.00 (0.00%)
After hours: 5:00PM EDT
|Bid||59.95 x 1400|
|Ask||61.90 x 1000|
|Day's Range||60.40 - 62.00|
|52 Week Range||10.05 - 62.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||72.20|
LONDON, UK / ACCESSWIRE / July 17, 2018 / If you want a free Stock Review on TXMD sign up now at www.wallstequities.com/registration. On Monday, July 16, 2018, the NASDAQ Composite and the S&P 500 edged 0.26% and 0.10% lower, respectively at the closing bell, while the Dow Jones Industrial Average stayed bullish, finishing marginally higher by 0.18%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: IDEXX Laboratories Inc. (NASDAQ: IDXX), Palatin Technologies Inc. (NYSE AMER: PTN), TherapeuticsMD Inc. (NASDAQ: TXMD), and Zogenix Inc. (NASDAQ: ZGNX).
While the Dow reclaimed its above 25,000 levels after almost a month Nasdaq is at a record high. The Dow Jones Industrial Average gained 0.38 percent to close at 25,019.41, while the S&P 500 Index increased 0.11 percent to close at 2,801.31. The Nasdaq Composite Index climbed 0.03 percent to close at 7,825.98.
Zogenix's (ZGNX) shares rally after successful completion of confirmatory phase III study of ZX008 for treating Dravet syndrome.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 12) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Arbutus Biopharma ...
NEW YORK, NY / ACCESSWIRE / July 13, 2018 / An analyst at Cantor Fitzgerald thinking that Galmed Pharmaceuticals is undervalued in the NASH space had traders cheering on Thursday, sending shares higher ...
Today, Zogenix stock is trading at $55.72, which represents a ~20.35% rise from yesterday’s close of $46.30. Zogenix also hit a 52-week high of $58.30 today, and yesterday’s closing price was ~361% higher than its 52-week low of $10.05 on August 11, 2017.
Zogenix (NASDAQ:ZGNX) shares were soaring on Thursday following the results of the company’s anti-seizure drug, which has proven to be effective in its latest clinical trial. The drugmaker developed a drug designed to treat a rare form of childhood epilepsy and it has reportedly been effective in reducing convulsive seizures in a second late-stage trial, with the company’s stock soaring as much as 26% earlier in the day thanks to these results. The move from Zogenix means that the drug is one step closer to coming to the market to treat Dravet syndrome. The ailment affects an estimated 20,000 patients in the U.S. but current treatments only include a combination of seizure medication and drugs to prevent emergencies.
Zogenix Inc said on Thursday its drug to treat a rare form of childhood epilepsy reduced convulsive seizures in a second late-stage trial, sending the drug developer's shares up as much as 26 percent. The successful trial takes the company one step closer to bringing the drug to the market, and comes close on the heels of regulatory approval for GW Pharmaceuticals Plc's cannabis-based treatment for the same form of epilepsy. Current treatment options for Dravet syndrome, which affects an estimated 20,000 patients in the United States, are limited to a combination of seizure medication and drugs to prevent emergencies.
The company said the Phase 3 study of its investigational drug ZX008 met its primary endpoint of reducing convulsive seizure frequency, as well as secondary endpoints. "These impressive study results show the significant impact the addition of ZX008 made in reducing the burden of convulsive seizures for patients who are not adequately controlled using stiripentol, the standard of care for the treatment of Dravet syndrome in Europe," said Professor Rima Nabbout, M.D., Ph.D., Department of Pediatric Neurology, Reference Center for Rare Epilepsies, Necker Enfants Malades Hospital, and Principal Investigator of the trial, called Study 1504.
Zogenix Inc said on Thursday its drug to treat Dravet syndrome, a rare form of epilepsy, met the main goal of a late-stage trial. The study, the second late-stage trial of the drug, found that the treatment ...
Primary Endpoint Achieved- Statistically Significant Convulsive Seizure Reduction for ZX008 versus Placebo for Adjunctive Treatment of Seizures. ZX008 Also Demonstrated Statistical Significance in All ...
The awards were made on July 2, 2018 under Zogenix’s Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix as an inducement to join the company. Mr. Sagrolikar was granted inducement awards consisting of options to purchase 100,000 shares of Zogenix common stock and 15,000 restricted stock units.
Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Ashish Sagrolikar has joined the Company as Executive Vice President and Chief Commercial Officer. Mr. Sagrolikar has over 25 years of global pharmaceutical sales, marketing and operations experience. Prior to joining Zogenix, he spent the last 16 years leading commercial strategies for rare disease and specialty pharmaceutical products, most recently at GlaxoSmithKline (GSK) and Baxter International.
At first glance, GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) is one of those investments that should be moving higher, but it GWPH stock isn’t. Analysts recognize the pharmaceutical company for its alternative therapies, specifically involving cannabidiol (CBD). Just recently, regulatory officials granted their CBD-based, anti-seizure drug Epidiolex the green light.
Stock Research Monitor: ZGNX, DEPO, and DRRX LONDON, UK / ACCESSWIRE / June 7, 2018 / If you want a free Stock Review on ENDP sign up now at www.wallstequities.com/registration . Ahead of today's trading ...
The awards were made on June 1, 2018 under Zogenix’s Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix as an inducement to join the company. The inducement awards consist of options to purchase an aggregate of 28,200 shares of Zogenix common stock. The options have a ten-year term and an exercise price equal to $42.50, the fair market value of Zogenix common stock on the date of grant. The options vest over a four-year period, with 25% of the options vesting on the first anniversary of each employee’s respective start date and the remainder vesting in equal monthly installments over the three years thereafter. The awards were approved by the independent compensation committee of Zogenix’s board of directors and were granted as an inducement material to the new employees entering into employment with Zogenix in accordance with Nasdaq Marketplace Rule 5635(c)(4).